Anyone who seriously invests in biotechs takes the time to understand what they are dealing with.
When dealing with a revolutionary therapy that the FDA must develop ways of assessing, is clearly not something you set your watch by or sweat the timing of.
Pretending to mourn the loss of the departed investor souls since 2004 is a very cheap and sensationalist effort, especially since potential patients for MSB's therapies have been left to languish and die.
Yet you don't mourn those lost souls. Why would that be? Trying to trigger the emotions of holders? So transparent of you!
Ann: Annual Report to Shareholders, page-75
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |